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Abstract
Background: The intratracheal instillation of bleomycin in mice induces early damage to alveolar epithelial cells
and development of inflammation followed by fibrotic tissue changes and represents the most widely used model
of pulmonary fibrosis to investigate human IPF.
Histopathology is the gold standard for assessing lung fibrosis in rodents, however it precludes repeated and
longitudinal measurements of disease progression and does not provide information on spatial and temporal
distribution of tissue damage.
Here we investigated the use of the Micro-CT technique to allow the evaluation of disease onset and progression
at different time-points in the mouse bleomycin model of lung fibrosis. Micro-CT was throughout coupled with
histological analysis for the validation of the imaging results.
Methods: In bleomycin-instilled and control mice, airways and lung morphology changes were assessed and
reconstructed at baseline, 7, 14 and 21 days post-treatment based on Micro-CT images. Ashcroft score, percentage
of collagen content and percentage of alveolar air area were detected on lung slides processed by histology and
subsequently compared with Micro-CT parameters.
Results: Extent (%) of fibrosis measured by Micro-CT correlated with Ashcroft score, the percentage of collagen
content and the percentage of alveolar air area (r2 = 0.91; 0.77; 0.94, respectively). Distal airway radius also correlated
with the Ashcroft score, the collagen content and alveolar air area percentage (r2 = 0.89; 0.78; 0.98, respectively).
Conclusions: Micro-CT data were in good agreement with histological read-outs as micro-CT was able to quantify
effectively and non-invasively disease progression longitudinally and to reduce the variability and number of
animals used to assess the damage. This suggests that this technique is a powerful tool for understanding
experimental pulmonary fibrosis and that its use could translate into a more efficient drug discovery process,
also helping to fill the gap between preclinical setting and clinical practice.
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Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sively fatal lung disease characterized by fibroblast pro-
liferation and extracellular matrix remodeling. IPF
etiology is unknown and possesses the worst prognosis
among all interstitial lung diseases, with a median sur-
vival of 2–4 years after diagnosis [1].
The pathogenesis of IPF is not fully understood. It has
been hypothesized that multiple cycles of lung injuries lead
to destruction of epithelial alveolar cells that in turn cause
the migration, proliferation and activation of mesenchymal
cells and the exaggerated accumulation of fibroblasts and
myofibroblasts. This induces an excessive collagen depos-
ition within the lung interstitium and alveolar space,
mirroring abnormal wound repair [1, 2]. In humans, IPF
manifests histopathologically as usual interstitial pneumo-
nia (UIP) and as subpleural and basal predominant reticula-
tion with honeycombing on high-resolution computed
tomography (HRCT) of the chest [3].
Bleomycin is a glycosylated linear non-ribosomal pep-
tide antibiotic produced by the bacterium Streptomyces
verticillus. Bleomycin has potent tumor killing proper-
ties, which have given it an important role in cancer
chemotherapy for curable diseases such as germinative
tumors and Hodgkin’s lymphoma. However, the major
limitation of bleomycin therapy is pulmonary toxicity
which can be life threatening in up to 10% of the pa-
tients receiving the drug [4–6].
Based on these evidences, bleomycin is the most
widely used drug for the induction of experimental pul-
monary fibrosis. The bleomycin model has many advan-
tages: it is easy to perform, widely accessible and highly
reproducible [7, 8].
Whilst lung bleomycin administration is considered the
easiest and the most reproducible way to induce consist-
ent lung fibrosis in rodents, concerns remain with regard
to the temporal aspects of the model and the translation
of the results to the clinic. The bleomycin model has two
distinct phases: the inflammatory stage that develops
within the first 2 weeks after the injury, which then sub-
sides to the fibrotic phase. It is now evident that targeting
mechanisms occurring during the inflammatory phase are
not likely to translate into a clinical benefit and that in
order to determine new drugs efficacy their testing must
be performed during the fibrotic phase [9].
The conventional assessment tools used in the bleo-
mycin model [9] are terminal and primarily based on
labor-intensive histology and quantitative assessment of
biochemical biomarkers (i.e. hydroxyproline levels and
lung collagen content) [10–12]. These parameters are
known to be highly variable among animals and repre-
sent only a snapshot at a given time-point of a far more
complex and dynamic biological process. Neither histo-
pathology nor biochemical analysis provide information
about the temporal and spatial distribution of the fi-
brotic lesion over the course of the study. Moreover, the
tendency for a spontaneous resolution of the fibrotic le-
sion, its patchy distribution with some areas of the lung
unaffected, and possible sampling errors with regard to
the selection and the number of fields to be analyzed,
are additional shortcomings that hamper successful
translation of the results to the clinic.
Recently, non-invasive Magnetic Resonance (MRI), Micro-
Computer Tomography (Micro-CT) and optical techniques
have been applied to longitudinal monitoring of airway
remodeling and inflammation in murine models [13–17].
In particular, lung Micro-CT providing high air-tissue
contrast is being increasingly used in pulmonary re-
search for the investigation of lung fibrosis in experi-
mental animals. Initial evidence suggests that by using
this imaging modality it is possible to quantify early
pathological changes associated with pulmonary fibrosis
that correlate to histopathological findings [18–20].
Indeed, serial Micro-CT based analysis as compared
with classical histological approaches results in quantita-
tive datasets that should allow for longitudinal assess-
ment, comparison among different treatment groups
including the effect of therapeutic intervention and de-
tailed tomographic information documenting the extent
of the disease in the individual animal.
Macro-CT and Micro-CT based functional respiratory
imaging (FRI) has demonstrated to be a powerful tool to
look at disease progression in IPF. Using FRI, different
studies have been performed in both human subjects
and animal models to assess the response to drug and
intervention therapy [21–23], to assist in better diagno-
sis [24] and to study regional variations in lung structure
and function [25].
In this study, we intended to quantify longitudinally
lung fibrosis progression and airway radius changes by
using a semi-automated algorithm at different time-
points after bleomycin administration in mice starting
from baseline and at days 7, 14 and 21. Furthermore,
complementary histological measurements were per-
formed at all time-points to validate the outcome of the
serial Micro-CT investigation.
Methods
Experimental set up
Sixty mice were randomly assigned to receive either sa-
line or bleomycin (dose) and were double instilled intra-
tracheally on day 0 and 4. Lungs were harvested in 5
animals per group for histological analysis at 7, 14 and
21 days after the first treatment. Parallel groups of 5 ani-
mals for each treatment arm were imaged with micro-
CT at the same time-points and the lungs harvested
soon after the scanning to assess the correlation between
micro-CT with histological data.
Ruscitti et al. Multidisciplinary Respiratory Medicine  (2017) 12:8 Page 2 of 10
Experimental animals
C57Bl/6 female mice, 8–9 weeks supplied by San Pietro
NatisoneHorst, The Netherlands (UD), were used. Prior
to use, animals were acclimatized for at least 7 days to
the local vivarium conditions (room temperature: 20–
24 °C; relative humidity: 40–70%; 12-h light–dark cycle),
having free access to standard rodent chow and softened
tap water. All animal experiments described herein were
approved by the intramural animal-welfare committee
for animal experimentation of Chiesi Farmaceutici and
ERASMUS MC under protocol number: EMC 3349
(138-14-07) comply with the European Directive 2010/
63 UE, Italian D.Lgs 26/2014 and the revised “Guide for
the Care and Use of Laboratory Animals” [10].
Bleomycin administration
For intratracheal administrations, 50 μl/mouse either
saline or bleomycin sulphate from Streptomyces
Verticillus (Sigma B2434) (1 mg/Kg) dissolved in saline
were instilled into the tracheal lumen through a cannula
under isoflurane (2.5% in oxygen) anaesthesia. The pro-
cedure was performed using a small laryngoscope
(Penn-Century Inc., Philadelphia, U.S.A.) to visualise the
epiglottis and ensure a good positioning of the cannula
into the tracheal lumen. Bleomycin or saline were
injected at day 0 and at day 4 (Fig. 1).
Micro-CT scanning
After mice were anaesthetized with isoflurane, the mouse
lung imaging was performed with a Quantum FX Micro-
CT scanner (PerkinElmer, Inc., Waltham, MA) using a
cardio-respiratory gated technique as reported previously
(PMID: 26967592). The X-ray system of the scanner uses a
microfocus tube with a focal spot size of 5 μm at 4 W and
produces X-rays in a cone-beam geometric formation. The
detection system of the scanner is composed of an amorph-
ous silicon digital X-ray plat panel which can acquire
projection radiographs at 30 frames per second. The images
were acquired with the X-ray tube set to 90 kVp, 160 μA
and projection radiographs were taken throughout the 360°
gantry rotation for a total scan time of 4.5 min. The entire
set of projection radiographs was retrospectively gated
using proprietary intrinsic image-based gating and then
reconstructed at functional residual capacity (FRC) by a
modified Feldkamp cone-beam filtered back-projection
algorithm. The reconstructed volume was 20 × 20 ×
20 mm and the voxel size was 40 × 40 × 40 μm.
Image processing
Micro-CT data were analyzed by an independent company
(FLUIDDA NV, Belgium)
Micro-CT scan data was converted into 3D models of
airways, lung lobes and fibrosis using Mimics 15
(Materialise, Leuven, Belgium) a previously validated
software package (Food and Drug Administration,
K073468; Conformité Européenne certificate, BE 05/
1191.CE.01). Airways and lungs were obtained based on
thresholding segmentation. Lungs were split into lobes
by identification of the fissure lines from the CT scan.
We identified lobes as: Right Cranial Lobe (RCrL), Right
Middle Lobe (RMdL), Right Caudal Lobe (RCdL), Right
Accessory Lobe (RAcL) and Left Lung (LL) (Fig. 5b).
Airway models were split into trachea and airways
leading to each previously defined lobe (Fig. 5a). Airway
radius was given by the average airway lumen radius per
zone. The FRI fibrosis parameter was obtained based on
thresholding segmentation and consequent intersection
with the lobe masks in order to obtain regional informa-
tion. Since blood is not a natural contrast on CT images,
if no contrast agent is added when performing the scan,
no distinction can be made between blood vessels and
fibrosis. For that reason, the FRI fibrosis parameter is
often a combination of blood vessels and fibrosis.
Fig. 1 Experimental timeline for bleomycin-induced lung mouse fibrosis. Sixty C57Bl/6 female were randomly assigned to receive either saline or
bleomycin (dose) and were double instilled intratracheally on day 0 and 4. Lungs were harvested in 5 animals per group for histological analysis
at 7, 14 and 21 days after the first treatment. Parallel groups of 5 animals for each treatment arm were imaged with micro-CT at the same
time-points and the lungs harvested soon after the scanning to assess the correlation between micro-CT with histological data
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Histology
Mice were sacrificed and lungs were removed and
inflated with a cannula through the trachea by gentle
infusion with 0.6 ml of 10% neutral-buffered formalin.
The lungs were then placed in a vial containing 10%
formalin and fixed for 24 h. For histological assessment,
the whole lungs were dehydrated in graded ethanol
series, clarified in xylene and paraffin embedded.
Sections of 5 μm thick were cut with a rotary micro-
tome (Reichert-Jung 1150/Autocut) in dorsal plane. The
sections were Masson’s trichrome stained according to
the manufacturer’s specifications (Histo-Line Laborator-
ies). For analysis the whole-slide imaging were acquired
by the NanoZoomer S-60 Digital slide scanner (Hama-
matsu). Fibrotic lung injury was assessed morphologic-
ally by semi-quantitative and quantitative parameters as
follow. Two independent pathologists with experience in
animal models of lung fibrosis performed blind histo-
logical analysis of the specimens/slides.
Ashcroft score
Morphological changes in lung sections were graded
semi-quantitatively according to the scale defined by
Ashcroft [26] modified by H bner et al. [27]. All the
parenchyma in the lung sections were assessed by a sys-
tem of 0–8 score. In every field (20× magnification
microscopic field), the predominant degree of fibrosis
was recorded as that occupying more than half of the
field area. The final score was expressed as a mean of in-
dividual scores observed on all microscopic fields.
Collagen content
The degree of fibrosis was quantified by the NIS-AR image
analysis software (Nikon). As ROIs three 10× magnification
1.1 × 0.9 mm, randomly selected were considered per each
slide. By standardization of image contrast, brightness and
colour threshold settings, the image analysis program was
configured to detect areas of green-stained collagen within
each ROI. The collagen content is expressed as a percent-
age of collagen deposition area (μm2) referred to the lung
total area (μm2) within the ROI. Bronchi and blood vessels
has been removed from the ROI area.
Alveolar air area
As an indirect parameter of fibrosis the alveolar air area was
quantified. By mean of the same software and ROIs applied
for the fibrosis fraction, the air area within the ROIs was
detected using a white threshold. The Air Area is expressed
as a percentage of area (μm2) occupied by air referred to the
lung total area (μm2) within the ROI. Bronchi and blood
vessels has been removed from the ROI area.
Data analysis
Data are expressed as the mean and the standard error of
the mean (s.e.m.). Statistical analysis was performed using
one-way ANOVA followed by Dunnett’s t test for multiple
comparison (PRISM Statistical software v 4.0.3). *p < 0.05,
**p < 0.01 was considered a level of statistical significance.
Results
Development of pulmonary fibrosis induced by intratra-
cheal administration of bleomycin in mice is often un-
predictable. There is a high degree of variability among
individual animals in the extent of fibrosis and the fibro-
sis often tends to resolve spontaneously if inhaled bleo-
mycin is administered as single shot. This represents a
real limitation for pharmacological studies due to the re-
stricted time window available for testing new drugs as
therapeutic intervention.
To overcome these issues, in the present study we
have used a double instillation of bleomycin for inducing
a more robust and reproducible lung fibrosis as detailed
in the experimental set up and described in Fig. 1.
Masson’s trichrome staining was used to stage the sever-
ity of the fibrosis by Ashcroft score and to quantify colla-
gen content percentage and alveolar air area fraction
percentage (Fig. 2e, f and g). Representative images of
histological sections stained with Masson’s trichrome
showing the fibrosis progression of saline and bleomycin-
treated mice at the designated time-points are shown in
Fig. 2a, b, c, and d.
Histopathological examination revealed that bleomycin
induced a fibrotic pattern characterized by a patchy dis-
tribution of the fibrotic foci in the lung parenchyma that
lead to a marked geographic heterogeneity in the distri-
bution of fibrosis within the same lobe.
In the bleomycin-treated groups, the Ashcroft score
was significantly increased for the whole duration of the
study compared with the saline groups (Fig. 2e). Single
fibrotic masses were evident starting from day 7 (Score
4) (Fig. 2b) and evolved into confluent conglomerates of
substitutive collagen at day 14 (Score 4.83) (Fig. 2c). At
day 21, the fibrotic score remained stable (Score 4.76)
(Fig. 2d), and no changes in morphological distribution
and appearance of fibrosis pattern were revealed. The
saline-treated group, as expected, showed normal lung
architecture (Score <1) at all points of observation with
no prominent inflammation or fibrosis masses in the
parenchyma (Fig. 2a and e).
Histomorphometric analysis of the alveolar air area in
control animals revealed that this parameter was un-
changed at all time-points, representing around 70% of
total lung area. On the contrary, a significant decrease in
the alveolar air area percentage was observed in bleo-
mycin injured mice compared to control groups over
the course of the study (Fig. 2f ). Fully in agreement with
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the other two parameters measured, the collagen content
percentage was significant increased over the time in
bleomycin-treated mice compared with saline group
(Fig. 2g). Indeed, the areas of fibrosis that stained posi-
tively for collagen were increased at day 7, peaking at day
14 and remained stable till the last point of observation.
In Fig. 3, Micro-CT scan images from a 21 days saline-
treated mouse and the same bleomycin-treated mice at
baseline, 7, 14 and 21 days are shown, highlighting the
capability of Micro-CT to visualize longitudinally the pro-
gressive anatomical changes of the lung architecture, well
visible if compare to the saline-treated mice projections.
To compare the 2-dimensional histological analysis
with the Micro-CT images, the lungs were embedded in
paraffin in order to maintain their body position and cut
along the dorsal plane. Once the serial sections were cut
and stained, the corresponding Micro-CT images were
identified based on the bronchial tree and the paren-
chyma structure. For each observation time-point a sat-
isfactory structural matching between the histology
slides and the Micro-CT projections was identified. A
representative matching between Micro-CT images and
lung stained slides obtained from the same individual
mice treated either with saline or with bleomycin at
14 days is depicted in Fig. 4a, b, d, and e.
Lung tissue with normal architecture or characterized
by mild fibrotic changes, such as alveolar septum thick-
ening, partly enlarged and rarefied alveoli corresponding
to an Ashcroft score from 0 to 3 (Fig. 4b and c). The
Micro-CT technology was able to visualize and detect
the lung parenchyma showing a very well overlapping
with histology (Fig. 4a, b and c).
Single fibrotic masses or confluent conglomerates of
substitutive collagen and lesions corresponding to an
Ashcroft score of 4–5 (Fig. 4e and f) appeared as darker
grey areas in the Micro-CT images, Fig. 4d. In higher
density fibrotic areas, classified with an Ashcroft score
above 6 (Fig. 4e and g), confluent fibrotic masses were
present preventing air access to the alveoli. These re-
gions appeared as black areas in the Micro-CT pictures
(Fig. 4d), due to the missing air contrast. In order to
quantify the airway radius, airway models were split into
a central and a distal part, that anatomically is the intra-
pulmonary airway tract. Representative pictures of seg-
mented airways and lung lobes from the Micro-CT scan
data are shown in Fig. 5a and b, respectively.
The quantification of the airway radius and the per-
centage of fibrosis from the Micro-CT scan data of
saline and bleomycin-treated mice was performed at
baseline, 7, 14 and 21 days post-treatment (Fig. 5c
Fig. 2 Quantitative histological analysis of lung fibrosis progression in bleomycin mouse model. Representative images of Trichromic Masson-staining
of mice lung sections: of saline and bleomycin-treated mice over time. a saline, (b, c and d). Bleomycin treated mice at 7–14 and 21 respectively used
for the quantification (10×). Bars: 200 μm. Time course of disease progression of saline and bleomicyn-treated mice at 7, 14 and 21 days: e Ashcroft’s
score criteria, f Alveolar Air area percentage and g Collagen content percentage. The experiment was repeated three times and each point presents
the mean ± s.e.m of 10 animals, for total of 60 mice per experimental session. Changes were compared to the saline group using one-way ANOVA
followed by Dunnett’s t test for multiple comparison. *p < 0.05; **p < 0.01
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Fig. 4 Micro-CT and histology view-matching. a, d Micro-CT dorsal planes of saline and bleomycin-treated mouse at 14 days fitted with the
appropriate histological sections, b, e (10×) magnification of normal lung parenchyma of saline (c), moderately fibrotic (f) and heavily fibrotic lung
parenchyma of bleomycin-treated mice (g). The squares indicate the position and the matching among histology at low magnification and the
Micro-CT. The magnification of the green and black squares (c, f) indicate normal and moderately fibrotic parenchyma detected by histology and
Micro-CT, the red one (g) indicates the heavily fibrotic lung that appeared as black in the Micro-CT view. The respective Ashcroft scores are
represented in the right side of the figure
Fig. 3 Serial Micro-CT imaging during bleomycin-induced lung fibrosis. 3D Micro-CT imaging of progressive pulmonary fibrosis in a representative
saline and bleomycin-treated mouse over time. Mice were scanned weekly, from baseline to 21 days after induction
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and d). A statistical significant increase in fibrosis and
airway radius was found for all the time points of
observation between the saline and bleomycin-treated
mice (Fig. 5c and d), in agreement with histological
findings as described in Fig. 2e, f, and g.
The plots in Fig. 6 show the correlation between the
two Micro-CT FRI parameters evaluated, fibrosis and
distal airway radius, and the three histological measure-
ments: Ashcroft score, alveolar air area and collagen
content percentage. Distal airway radius expressed in
mm was plotted against Ashcroft score (Fig. 6a), colla-
gen content percentage (Fig. 6b) and alveolar air area
percentage (Fig. 6c), for the mean of each group at the
different time points. Linear regression analysis showed
Fig. 5 Segmentation and quantification of airways and lung lobes on Micro-CT. Airway models were split into a central and a distal part, that anatomically is
the intrapulmonary airway tract, leading to each defined lobe (a). Airway radius was evaluated with Micro-CT in the distal part of the airway tree of untreated
and treated mice with bleomycin at 7, 14 and 21 day (c). Lungs were split into lobes by identification of the fissure lines from the CT scan. Lobes were
identified as: Right Cranial Lobe (RCrL), Right Middle Lobe (RMdL), Right Caudal Lobe (RCdL), Right Accessory Lobe (RAcL) and Left Lung (LL) (b). Total lung
fibrosis was evaluate on Micro-CT of treated mice with saline or bleomycin at 7, 14 and 21 day (d). Each point presents the mean± s.e.m of 5 animals, for a total
of 30 mice. Changes were compared to the saline group using one-way ANOVA followed by Dunnett’s t test for multiple comparison. *p<0.05; **p< 0.01
Fig. 6 Correlation between Micro-CT and histological parameters. Airway radius (mm) correlation with: Ashcroft score (a), Collagen Content % (b)
and Alveolar Air Area% (c) Fibrosis (%) correlation with: Ashcroft score, (d), Collagen content % (e) and Alveolar Air area % (b). Each single dot
represents the mean ± s.e.m of 5 animals for a total of 30 mice
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that airway radius positively correlated with the classical
Ashcroft scoring (r2 = 0.91; p = 0.003), (Fig. 6a) and with
collagen content percentage (r2 = 0.77; p = 0.022),
(Fig. 6b) but negatively with the alveolar air area per-
centage as expected (r2 = 0.94; p = 0.001), (Fig. 6c).
The same correlation was performed using the FRI
fibrosis parameter. Fibrosis percentage was plotted
against: Ashcroft score (Fig. 6d), collagen content per-
centage (Fig. 6e) and alveolar air area percentage (Fig. 6f )
for the mean of each group at the different time points.
Linear regression analysis showed that fibrosis percent-
age positively correlated with the classical Ashcroft scor-
ing (r2 = 0.89; p = 0.005) (Fig. 6d) and with collagen
content percentage (r2 = 0.78; p = 0.019) (Fig. 6e), but
negatively correlated with the alveolar air area percent-
age as expected (r2 = 0.98; p < 0.001) (Fig. 6f ).
These findings were consistent and demonstrate that
FRI parameters from Micro-CT can serve as a reliable
indication of the fibrotic changes occurring in the lung
parenchyma.
Discussion
Despite recent advances in therapeutics available for IPF,
there is a continued need to find more effective therap-
ies to prevent or reverse lung fibrosis [28]. Moreover,
the only treatment proven effective in prolonging sur-
vival is lung transplantation with a post-transplantation
5-year survival for IPF patients of approximately 44%
[29]. The development of novel therapies relies on how
well experimental animal models are able to translate
findings to clinical outcomes but there is still much de-
bate around the reliability of current animal models for
pulmonary fibrosis [28]. Single bleomycin administration
in mice produces fibrotic lesions with an high degree of
variability among individual animals and, moreover, the
fibrosis tends to resolve spontaneously.
In order to overcome some of the intrinsic animal
modelling limitations, we have set up a more robust and
reproducible lung fibrosis mouse model that requires a
double instillation of bleomycin as detailed in Fig. 1. In
vivo imaging in small animal models is a powerful tool
to visualize disease progression, to assess their topo-
graphical distribution and to qualitatively evaluate the
severity in a non-invasive manner. This approach may
help to fill the gap between preclinical setting and clin-
ical practice [30].
In the present work we monitored the lung fibrosis in
bleomycin-induced mouse model by using Micro-CT
technology coupled to classical histology. The major
limitation of the conventional assessments of fibrosis re-
lies on invasive ex vivo measurements. These method-
ologies produce solid and reproducible data, but could
be biased from sampling methods. In fact, only a small
fraction of the total lung is accounted for the histological
evaluation of Ashcroft score, and histomorphometric
measurements of collagen content percentage and alveo-
lar air area fraction.
Moreover, mice need to be sacrificed at each time
point in order to have a sufficient number for statistical
power, precluding the possibility to monitor the disease
progression in the same subject. When a mouse is sacri-
ficed and disappears from the experimental setting, a
missing information is generated in the biological sys-
tem. The missing information cannot be retrieved any-
more and performing new studies may increase
biological variability. Micro-CT seems to be an ideal
technology for quantifying pulmonary disease progres-
sion lung parenchyma, remodeling and the bronchial
tree changes. Micro-CT approach assures that the entire
lung is assessed in each animal, while the conventional
tools are limited [31].
In this study Micro-CT was used to quantify longitudin-
ally disease progression by evaluating two parameters: air-
way radius in the distal part of the bronchial tree (Fig. 5a)
and fibrosis percentage in the lung parenchyma (Fig. 5b).
However, the Micro-CT revealed a limitation on the fibro-
sis percentage detection at early time points. (Fig. 5d). It is
bleomycin treatment induced an inflammatory phase [32]
and there is a balance between inflammation and fibrosis
at day 7 resulting with slightly overestimation of fibrosis
percentage parameter measured by Micro-CT compare to
histology. The Micro-CT projections of the lungs present-
ing mild or moderate degree of fibrosis areas with an Ash-
croft score (0–4) found a perfect match with histology
(Fig. 4a, b, c, and f). The fibrosis pattern is characterized
by a patchy distribution of the fibrotic lesions containing
some areas with a high degree of fibrosis with an Ashcroft
score (5- > 6), Fig. 4d, e and g. These zones in Micro-CT
images appeared darker till almost become black corre-
sponding to an increase in severity of fibrosis, due to the
missing contrast from the alveolar air space, limiting the
possibility to overlap Micro-CT images with histology.
Despite some technical limitations, the correlation plots
(Fig. 6) clearly highlight convincing thresholds for each
histological parameter and Micro-CT allowed the quantifi-
cation of distal airway radius and fibrosis (Fig. 5c and d).
An increase of the distal airway radius parameter could
be explained by the obliteration of the alveoli and the con-
sequent airflow limitation. This could lead to the airway
tree dilation as a compensatory phenomenon, which ex-
plains the very good correlation found with Ashcroft score
and alveolar air area percentage (Fig. 6a and c) and even
though weaker, a significant correlation between airway
radius and collagen content (%) was also obtained.
FRI fibrosis parameter increased over the time points of
observation. Additionally, the amazing correlation found
with alveolar air area percentage (r2 = 0.98), (Fig. 6f) and
with Ashcroft score and collagen content demonstrated
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that lung parameters from Micro-CT serve as a reliable
indicator of the typical lung changes in IPF pathology,
involving: airspace fibrosis, alveolar collapse and decrease
in the gas-exchange tissue surface.
Moreover, the capability of Micro-CT technology to
quantify the fibrosis and the airway radius changes is
more likely to reflect directly in the pathologic and also
therapeutic changes in the lungs.
Even though the Micro-CT cannot be used as a stand-
alone technology at the moment, it seems to be comple-
mentary to histology. Micro-CT can provide the 3D
model while histology provides more accurate informa-
tion on the cellular and molecular level.
Our approach with Micro-CT in future drug efficacy
studies would be to obtain baseline evaluation of each ani-
mal before fibrosis is induced, then confirmation of fibrosis
before the treatment is initiated and finally evaluation of
potential treatment effects within the therapeutic window.
We believe that this approach represents a smart tool to
evaluate drug efficacy and eventually will prove to be superior
compared to terminal assessment for drug discovery [31].
Nowadays is well known that drug effects are crucially
dependent on timing of compound administration and
that the testing of anti-fibrotic agents must be performed
during a specific fibrotic phase of the animal model [33].
This limitation can be overcome using Micro-CT scan: all
the mice could be screened before entering in the drug
treatment and divided according to the severity of the dis-
ease. The huge advantage is that each mouse considered
as a single subject could be the control of itself; and an in-
terim analysis of drug efficacy could be performed in order
to guide and plan in advance the future experiments.
Conclusions
Drug discovery process is very expensive and unproductive,
[34–36] and there is a huge medical need for treating IPF
patients. The in vivo study, that recapitulates the pathogen-
esis, the lesions as well as the effect of a drug on the disease
outcome, represents the main obstacle to be overcome
during the last steps of development of such molecules.
This combination of better animal models, Micro-CT tech-
nology together with histology data allowed a more accurate
interpretation of the data obtained in vivo. The possibility to
analyze more parameters from the Micro-CT is fundamental
in order to fully describe and better understand dynamic pro-
cesses during IPF disease onset, progression and therapy.
Taken together, our findings underline the importance
of the possibility to accurately quantify specific parameters
to follow disease progression in a non-invasive way. We
strongly believe that Micro-CT applied to the fibrosis
research field could allow longitudinally studies reducing
the variability and number of animals used and may,
therefore, provide a novel tool for understanding pulmon-
ary fibrosis onset, progression and therapy.
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